메뉴 건너뛰기




Volumn 37, Issue 2, 2017, Pages 283-299

Biologic Therapies for Autoimmune and Connective Tissue Diseases

Author keywords

Ankylosing spondylitis; Biologic therapy; Gout; Lupus; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BELIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

EID: 85014126009     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2017.01.005     Document Type: Review
Times cited : (22)

References (78)
  • 1
    • 0035932519 scopus 로고    scopus 로고
    • Cytokine pathways and joint inflammation in rheumatoid arthritis
    • 1 Choy, E.H.S., Panayi, G.S., Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001), 907–916.
    • (2001) N Engl J Med , vol.344 , pp. 907-916
    • Choy, E.H.S.1    Panayi, G.S.2
  • 2
    • 0029044362 scopus 로고
    • American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
    • 2 Felson, D.T., Anderson, J.J., Boers, M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:6 (1995), 727–735.
    • (1995) Arthritis Rheum , vol.38 , Issue.6 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3
  • 3
    • 5444231338 scopus 로고    scopus 로고
    • Remission in rheumatoid arthritis: agreement of the Disease Active Score (DAS28) with the ARA preliminary remission criteria
    • 3 Fransen, J., Creemers, M.C.W., Van Riel, P.L., Remission in rheumatoid arthritis: agreement of the Disease Active Score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1 (2004), 1252–1255.
    • (2004) Rheumatology (Oxford) , vol.43 , Issue.1 , pp. 1252-1255
    • Fransen, J.1    Creemers, M.C.W.2    Van Riel, P.L.3
  • 4
    • 33750331541 scopus 로고    scopus 로고
    • Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors
    • 4 Fransen, J., Antoni, C., Mease, P.J., Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:10 (2006), 1373–1378.
    • (2006) Ann Rheum Dis , vol.65 , Issue.10 , pp. 1373-1378
    • Fransen, J.1    Antoni, C.2    Mease, P.J.3
  • 5
    • 33845482745 scopus 로고    scopus 로고
    • A systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    • xi-xiii, 1–229
    • 5 Chen, Y.F., Jobanputra, P., Barton, P., A systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:42 (2006), iii–iv xi-xiii, 1–229.
    • (2006) Health Technol Assess , vol.10 , Issue.42 , pp. iii-iv
    • Chen, Y.F.1    Jobanputra, P.2    Barton, P.3
  • 6
    • 58749116632 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal
    • 6 Caporali, R., Pallavicini, R.B., Filippini, M., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8 (2009), 274–280.
    • (2009) Autoimmun Rev , vol.8 , pp. 274-280
    • Caporali, R.1    Pallavicini, R.B.2    Filippini, M.3
  • 7
    • 77950300568 scopus 로고    scopus 로고
    • Switching TNF-alpha antagonist in rheumatoid arthritis: the experience of the Lorhen registry
    • 7 Caporali, R., Sarzi-Puttini, P., Atzeni, F., et al. Switching TNF-alpha antagonist in rheumatoid arthritis: the experience of the Lorhen registry. Autoimmun Rev 9:6 (2010), 465–469.
    • (2010) Autoimmun Rev , vol.9 , Issue.6 , pp. 465-469
    • Caporali, R.1    Sarzi-Puttini, P.2    Atzeni, F.3
  • 8
    • 84901807842 scopus 로고    scopus 로고
    • TNF inhibitor therapy for rheumatoid arthritis
    • 8 Ma, X., Xu, S., TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:2 (2013), 177–184.
    • (2013) Biomed Rep , vol.1 , Issue.2 , pp. 177-184
    • Ma, X.1    Xu, S.2
  • 9
    • 84960102585 scopus 로고    scopus 로고
    • Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis
    • 9 Santos-Moreno, P., Sanchez, G., Gomez, D., et al. Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis. J Clin Rheumatol 22:2 (2016), 57–62.
    • (2016) J Clin Rheumatol , vol.22 , Issue.2 , pp. 57-62
    • Santos-Moreno, P.1    Sanchez, G.2    Gomez, D.3
  • 10
    • 84862563304 scopus 로고    scopus 로고
    • A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
    • 10 Greenberg, J.D., Reed, G., Decktor, D., et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71 (2012), 1134–1142.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1134-1142
    • Greenberg, J.D.1    Reed, G.2    Decktor, D.3
  • 11
    • 84855833408 scopus 로고    scopus 로고
    • Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis
    • 11 Aaltonen, K.J., Virkki, L.M., Malmivaara, A., et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One, 7(1), 2012, e30275.
    • (2012) PLoS One , vol.7 , Issue.1 , pp. e30275
    • Aaltonen, K.J.1    Virkki, L.M.2    Malmivaara, A.3
  • 12
    • 33749363027 scopus 로고    scopus 로고
    • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    • 12 Maini, R.N., Taylor, P.C., Szechinski, J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:9 (2006), 2817–2829.
    • (2006) Arthritis Rheum , vol.54 , Issue.9 , pp. 2817-2829
    • Maini, R.N.1    Taylor, P.C.2    Szechinski, J.3
  • 13
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    • 13 Emery, P., Keystone, E., Tony, H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:11 (2008), 1516–1523.
    • (2008) Ann Rheum Dis , vol.67 , Issue.11 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3
  • 14
    • 84894901070 scopus 로고    scopus 로고
    • Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums
    • 14 Navarro, G., Taroumian, S., Barroso, N., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 43 (2014), 458–469.
    • (2014) Semin Arthritis Rheum , vol.43 , pp. 458-469
    • Navarro, G.1    Taroumian, S.2    Barroso, N.3
  • 15
    • 54949150604 scopus 로고    scopus 로고
    • Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination with Traditional Disease-modifying Antirheumatic Drug Therapy study
    • 15 Genovese, M.C., McKay, J.D., Nasonov, E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination with Traditional Disease-modifying Antirheumatic Drug Therapy study. Arthritis Rheum 58:10 (2008), 2968–2980.
    • (2008) Arthritis Rheum , vol.58 , Issue.10 , pp. 2968-2980
    • Genovese, M.C.1    McKay, J.D.2    Nasonov, E.L.3
  • 16
    • 84877275257 scopus 로고    scopus 로고
    • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    • 16 Gabay, C., Emery, P., van Vollenhoven, R., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
    • (2013) Lancet , vol.381 , pp. 1541-1550
    • Gabay, C.1    Emery, P.2    van Vollenhoven, R.3
  • 17
    • 84889667445 scopus 로고    scopus 로고
    • A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
    • 17 Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:1 (2014), 69–74.
    • (2014) Ann Rheum Dis , vol.73 , Issue.1 , pp. 69-74
    • Burmester, G.R.1    Rubbert-Roth, A.2    Cantagrel, A.3
  • 18
    • 84896689880 scopus 로고    scopus 로고
    • Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis
    • 18 Ogata, A., Tanimura, K., Sugimoto, T., et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:3 (2014), 344–354.
    • (2014) Arthritis Care Res (Hoboken) , vol.66 , Issue.3 , pp. 344-354
    • Ogata, A.1    Tanimura, K.2    Sugimoto, T.3
  • 19
    • 85007277373 scopus 로고    scopus 로고
    • Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    • 19 Kivitz, A., Olech, E., Borofsky, M., et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:11 (2014), 1653–1661.
    • (2014) Arthritis Care Res (Hoboken) , vol.66 , Issue.11 , pp. 1653-1661
    • Kivitz, A.1    Olech, E.2    Borofsky, M.3
  • 20
    • 84942094202 scopus 로고    scopus 로고
    • Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis
    • 20 Ogata, A., Atsumi, T.A., Fukuda, T., et al. Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 67:10 (2015), 1354–1362.
    • (2015) Arthritis Care Res , vol.67 , Issue.10 , pp. 1354-1362
    • Ogata, A.1    Atsumi, T.A.2    Fukuda, T.3
  • 21
    • 84878155949 scopus 로고    scopus 로고
    • Subcutaneous abatacept for the treatment of rheumatoid arthritis
    • 21 Schiff, M., Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology 52 (2013), 986–997.
    • (2013) Rheumatology , vol.52 , pp. 986-997
    • Schiff, M.1
  • 22
    • 84897456352 scopus 로고    scopus 로고
    • Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial
    • 22 Genovese, M.C., Tena, C.P., Covarrubias, A., et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol 44:4 (2014), 629–639.
    • (2014) J Rheumatol , vol.44 , Issue.4 , pp. 629-639
    • Genovese, M.C.1    Tena, C.P.2    Covarrubias, A.3
  • 23
    • 84889641417 scopus 로고    scopus 로고
    • Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
    • 23 Schiff, M., Weinblatt, M.E., Valente, R., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73 (2014), 86–94.
    • (2014) Ann Rheum Dis , vol.73 , pp. 86-94
    • Schiff, M.1    Weinblatt, M.E.2    Valente, R.3
  • 24
    • 84876701598 scopus 로고    scopus 로고
    • Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study
    • 24 Nash, P., Nayiager, S., Genovese, M., et al. Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. Arthritis Care Res (Hoboken) 65:5 (2013), 718–728.
    • (2013) Arthritis Care Res (Hoboken) , vol.65 , Issue.5 , pp. 718-728
    • Nash, P.1    Nayiager, S.2    Genovese, M.3
  • 25
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • 25 Cohen, S.B., Emery, P., Greenwald, M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
    • (2006) Arthritis Rheum , vol.54 , pp. 2793-2806
    • Cohen, S.B.1    Emery, P.2    Greenwald, M.W.3
  • 26
    • 84870330803 scopus 로고    scopus 로고
    • Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5 year data from the REFLEX study
    • 26 Keystone, E.C., Cohen, S.B., Emery, P., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5 year data from the REFLEX study. J Rheumatol 39:12 (2012), 2238–2246.
    • (2012) J Rheumatol , vol.39 , Issue.12 , pp. 2238-2246
    • Keystone, E.C.1    Cohen, S.B.2    Emery, P.3
  • 27
    • 78650645377 scopus 로고    scopus 로고
    • Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
    • 27 Tak, P.P., Rigby, W.F., Rubbert-Roth, A., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:1 (2011), 39–46.
    • (2011) Ann Rheum Dis , vol.70 , Issue.1 , pp. 39-46
    • Tak, P.P.1    Rigby, W.F.2    Rubbert-Roth, A.3
  • 28
    • 77955896561 scopus 로고    scopus 로고
    • Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
    • 28 Emery, P., Deodhar, A., Rigby, W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:9 (2010), 1629–1635.
    • (2010) Ann Rheum Dis , vol.69 , Issue.9 , pp. 1629-1635
    • Emery, P.1    Deodhar, A.2    Rigby, W.F.3
  • 29
    • 33646483031 scopus 로고    scopus 로고
    • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
    • 29 Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:5 (2006), 1390–1400.
    • (2006) Arthritis Rheum , vol.54 , Issue.5 , pp. 1390-1400
    • Emery, P.1    Fleischmann, R.2    Filipowicz-Sosnowska, A.3
  • 30
    • 77955738274 scopus 로고    scopus 로고
    • Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)
    • 30 Rubbert-Roth, A., Tak, P.P., Zerbini, C., Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:9 (2010), 1683–1693.
    • (2010) Rheumatology (Oxford) , vol.49 , Issue.9 , pp. 1683-1693
    • Rubbert-Roth, A.1    Tak, P.P.2    Zerbini, C.3
  • 31
    • 84957991509 scopus 로고    scopus 로고
    • Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
    • 31 Chatzidionysiou, K., Lie, E., Nasonov, E., et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther, 18, 2016, 50.
    • (2016) Arthritis Res Ther , vol.18 , pp. 50
    • Chatzidionysiou, K.1    Lie, E.2    Nasonov, E.3
  • 32
    • 84907157319 scopus 로고    scopus 로고
    • Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
    • 32 Song, G.G., Bae, S.C., Lee, Y.H., Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med 29 (2014), 656–663.
    • (2014) Korean J Intern Med , vol.29 , pp. 656-663
    • Song, G.G.1    Bae, S.C.2    Lee, Y.H.3
  • 33
    • 84940176223 scopus 로고    scopus 로고
    • Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs
    • 33 Charles-Schoeman, C., Burmester, G., Nash, P., et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 75:7 (2016), 1293–1301.
    • (2016) Ann Rheum Dis , vol.75 , Issue.7 , pp. 1293-1301
    • Charles-Schoeman, C.1    Burmester, G.2    Nash, P.3
  • 34
    • 79952070370 scopus 로고    scopus 로고
    • Efficacy and safety of belimumab in patients with active systemic lupus erythematous: a randomized, placebo-controlled, phase 3 trial
    • 34 Navarra, S.V., Guzman, R.M., Gallacher, A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematous: a randomized, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731.
    • (2011) Lancet , vol.377 , pp. 721-731
    • Navarra, S.V.1    Guzman, R.M.2    Gallacher, A.E.3
  • 35
    • 82455198794 scopus 로고    scopus 로고
    • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus
    • 35 Furie, R., Petri, M., Zamani, O., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:12 (2011), 3918–3930.
    • (2011) Arthritis Rheum , vol.63 , Issue.12 , pp. 3918-3930
    • Furie, R.1    Petri, M.2    Zamani, O.3
  • 36
    • 84867398973 scopus 로고    scopus 로고
    • Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
    • 36 Manzi, S., Sánchez-Guerrero, J., Merrill, J.T., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:11 (2012), 1833–1888.
    • (2012) Ann Rheum Dis , vol.71 , Issue.11 , pp. 1833-1888
    • Manzi, S.1    Sánchez-Guerrero, J.2    Merrill, J.T.3
  • 37
    • 84863850571 scopus 로고    scopus 로고
    • Belimumab in the treatment of systemic lupus erythematous: high disease activity predictors of response
    • 37 van Vollenhoven, R.F., Petri, M.A., Crevera, R., et al. Belimumab in the treatment of systemic lupus erythematous: high disease activity predictors of response. Ann Rheum Dis 71:8 (2012), 1343–1349.
    • (2012) Ann Rheum Dis , vol.71 , Issue.8 , pp. 1343-1349
    • van Vollenhoven, R.F.1    Petri, M.A.2    Crevera, R.3
  • 38
    • 84866184129 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study
    • 38 Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:4 (2012), 1215–1226.
    • (2012) Arthritis Rheum , vol.64 , Issue.4 , pp. 1215-1226
    • Rovin, B.H.1    Furie, R.2    Latinis, K.3
  • 39
    • 74849131972 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: the randomized double-blind phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial
    • 39 Merrill, J.T., Neuwelt, C.M., Wallace, D.J., et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: the randomized double-blind phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial. Arthritis Rheum 62:1 (2010), 222–233.
    • (2010) Arthritis Rheum , vol.62 , Issue.1 , pp. 222-233
    • Merrill, J.T.1    Neuwelt, C.M.2    Wallace, D.J.3
  • 40
    • 77956288032 scopus 로고    scopus 로고
    • Off-label use of rituximab in systemic lupus erythematosus: a systemic review
    • 40 Murray, E., Perry, M., Off-label use of rituximab in systemic lupus erythematosus: a systemic review. Clin Rheumatol 29 (2010), 707–716.
    • (2010) Clin Rheumatol , vol.29 , pp. 707-716
    • Murray, E.1    Perry, M.2
  • 41
    • 84927511205 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematous: a systemic review
    • 41 Cobo-Ibanez, T., Loza-Santamaria, E., Pego-Reigosa, J.M., et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematous: a systemic review. Semin Arthritis Rheum 44 (2014), 175–185.
    • (2014) Semin Arthritis Rheum , vol.44 , pp. 175-185
    • Cobo-Ibanez, T.1    Loza-Santamaria, E.2    Pego-Reigosa, J.M.3
  • 42
    • 84976485492 scopus 로고    scopus 로고
    • Update on biological therapy for systemic lupus erythematosus
    • 42 Lobo Borba, H.H., Funke, A., Wiens, A., Update on biological therapy for systemic lupus erythematosus. Curr Rheumatol Rep, 18, 2016, 44.
    • (2016) Curr Rheumatol Rep , vol.18 , pp. 44
    • Lobo Borba, H.H.1    Funke, A.2    Wiens, A.3
  • 43
    • 84924812141 scopus 로고    scopus 로고
    • Treatment of lupus nephritis with abatacept and cyclophosphamide efficacy and safety study
    • 43 Askanase, A., Byron, M., Keyes-Elstein, L., et al. Treatment of lupus nephritis with abatacept and cyclophosphamide efficacy and safety study. Arthritis Rheum 66:11 (2014), 3096–3104.
    • (2014) Arthritis Rheum , vol.66 , Issue.11 , pp. 3096-3104
    • Askanase, A.1    Byron, M.2    Keyes-Elstein, L.3
  • 44
    • 84868126198 scopus 로고    scopus 로고
    • Abatacept for lupus nephritis: alternative definitions of complete remission support conflicting conclusions
    • 44 Wofsy, D., Hillson, J.L., Diamond, B., Abatacept for lupus nephritis: alternative definitions of complete remission support conflicting conclusions. Arthritis Rheum 64:11 (2012), 3660–3665.
    • (2012) Arthritis Rheum , vol.64 , Issue.11 , pp. 3660-3665
    • Wofsy, D.1    Hillson, J.L.2    Diamond, B.3
  • 45
    • 77957682858 scopus 로고    scopus 로고
    • The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematous
    • 45 Merrill, J.T., Burgos-Vargas, R., Westhovens, R., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematous. Arthritis Rheum 62:10 (2010), 3077–3087.
    • (2010) Arthritis Rheum , vol.62 , Issue.10 , pp. 3077-3087
    • Merrill, J.T.1    Burgos-Vargas, R.2    Westhovens, R.3
  • 46
    • 85016516013 scopus 로고    scopus 로고
    • Available at: Accessed June 29.
    • 46 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. Available at: https://clinicaltrials.gov/ct2/show/NCT01714817. Accessed June 29, 2016.
    • (2016)
  • 47
    • 85008312423 scopus 로고    scopus 로고
    • Rituximab in treatment of inflammatory myopathies: a review
    • 47 Fasano, S., Gordon, P., Hajji, R., et al. Rituximab in treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 55:7 (2016), 1318–1324.
    • (2016) Rheumatology (Oxford) , vol.55 , Issue.7 , pp. 1318-1324
    • Fasano, S.1    Gordon, P.2    Hajji, R.3
  • 48
    • 84873878655 scopus 로고    scopus 로고
    • Rituximab in the treatment of refractory adult and juvenile dermatomyositis and polymyositis: a randomized, placebo-phase trial
    • 48 Oddis, C.V., Reed, A.M., Aggarawal, R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:2 (2013), 314–324.
    • (2013) Arthritis Rheum , vol.65 , Issue.2 , pp. 314-324
    • Oddis, C.V.1    Reed, A.M.2    Aggarawal, R.3
  • 49
    • 84896277090 scopus 로고    scopus 로고
    • Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis
    • 49 Aggarwal, R., Bandos, A., Reed, A.M., et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 66 (2014), 740–749.
    • (2014) Arthritis Rheum , vol.66 , pp. 740-749
    • Aggarwal, R.1    Bandos, A.2    Reed, A.M.3
  • 50
    • 80052596202 scopus 로고    scopus 로고
    • A randomized, pilot trial of etanercept in dermatomyositis
    • 50 The Muscle Study Group, A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:3 (2011), 427–436.
    • (2011) Ann Neurol , vol.70 , Issue.3 , pp. 427-436
    • The Muscle Study Group1
  • 51
    • 84896890887 scopus 로고    scopus 로고
    • New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review
    • 51 Brunasso, A.M.G., Aberer, W., Massone, C., New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal, 2014, 2014, 179180.
    • (2014) ScientificWorldJournal , vol.2014 , pp. 179180
    • Brunasso, A.M.G.1    Aberer, W.2    Massone, C.3
  • 52
    • 85016495476 scopus 로고    scopus 로고
    • Abatacept for the treatment of refractory juvenile dermatomyositis. In: ClinicalTrials.gov [Internet]
    • National Library of Medicine (US) Bethesda (MD) Available at: Accessed Jun 28, 2016. NLM Identifier: NCT02043548
    • 52 George Washington University, Abatacept for the treatment of refractory juvenile dermatomyositis. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02043548 Accessed Jun 28, 2016. NLM Identifier: NCT02043548.
    • (2000)
    • George Washington University1
  • 53
    • 84954322760 scopus 로고    scopus 로고
    • Modern therapies for idiopathic inflammatory myopathies: role of biologics
    • 53 Moghadam-Kia, S., Oddis, C.V., Aggarawal, R., Modern therapies for idiopathic inflammatory myopathies: role of biologics. Clin Rev Allergy Immunol 52:1 (2017), 81–87.
    • (2017) Clin Rev Allergy Immunol , vol.52 , Issue.1 , pp. 81-87
    • Moghadam-Kia, S.1    Oddis, C.V.2    Aggarawal, R.3
  • 54
    • 85016471858 scopus 로고    scopus 로고
    • Tocilizumab in the treatment of refractory polymyositis and dermatomyositis. In: ClinicalTrials.gov [Internet]
    • National Library of Medicine (US) Bethesda (MD) Available at: Accessed Jun 28, 2016. NLM Identifier: NCT02594735
    • 54 University of Pittsburgh, Tocilizumab in the treatment of refractory polymyositis and dermatomyositis. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02594735 Accessed Jun 28, 2016. NLM Identifier: NCT02594735.
    • (2000)
    • University of Pittsburgh1
  • 55
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
    • 55 Garrett, S., Jenkinson, T., Kennedy, L.G., A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:12 (1994), 2286–2291.
    • (1994) J Rheumatol , vol.21 , Issue.12 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3
  • 56
    • 0034888069 scopus 로고    scopus 로고
    • Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
    • 56 Anderson, J.J., Baron, G., van der Heijde, D., Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:8 (2001), 1876–1886.
    • (2001) Arthritis Rheum , vol.44 , Issue.8 , pp. 1876-1886
    • Anderson, J.J.1    Baron, G.2    van der Heijde, D.3
  • 58
    • 84929633276 scopus 로고    scopus 로고
    • Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis
    • 58 Callhoff, J., Sieper, J., Weiß, A., et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74 (2015), 1241–1248.
    • (2015) Ann Rheum Dis , vol.74 , pp. 1241-1248
    • Callhoff, J.1    Sieper, J.2    Weiß, A.3
  • 59
    • 85018192886 scopus 로고    scopus 로고
    • Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systemic review and meta-analysis
    • 59 Maneiro, J.R., Souto, A., Salgado, E., et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systemic review and meta-analysis. RMD Open, 1(1), 2015, e000017.
    • (2015) RMD Open , vol.1 , Issue.1 , pp. e000017
    • Maneiro, J.R.1    Souto, A.2    Salgado, E.3
  • 60
    • 84952025973 scopus 로고    scopus 로고
    • Secukinumab, an IL-17A inhibitor in ankylosing spondylitis
    • 60 Baeten, D., Sieper, J., Braun, J., et al. Secukinumab, an IL-17A inhibitor in ankylosing spondylitis. N Engl J Med 373:26 (2015), 2534–2548.
    • (2015) N Engl J Med , vol.373 , Issue.26 , pp. 2534-2548
    • Baeten, D.1    Sieper, J.2    Braun, J.3
  • 61
    • 44349107161 scopus 로고    scopus 로고
    • Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systemic review and metaanalysis of randomized control trials
    • 61 Saad, A.A., Symmons, D.P.M., Noyce, P.R., et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systemic review and metaanalysis of randomized control trials. J Rheumatol 35 (2008), 883–890.
    • (2008) J Rheumatol , vol.35 , pp. 883-890
    • Saad, A.A.1    Symmons, D.P.M.2    Noyce, P.R.3
  • 62
    • 84969174614 scopus 로고    scopus 로고
    • Assessment of response to treatment, remission and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors
    • 62 Lubrano, E., Parson, W.J., Perrotta, F.M., Assessment of response to treatment, remission and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 43 (2016), 918–923.
    • (2016) J Rheumatol , vol.43 , pp. 918-923
    • Lubrano, E.1    Parson, W.J.2    Perrotta, F.M.3
  • 63
    • 84883134297 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial
    • 63 McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., et al., on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382 (2013), 780–789.
    • (2013) Lancet , vol.382 , pp. 780-789
    • McInnes, I.B.1    Kavanaugh, A.2    Gottlieb, A.B.3
  • 64
    • 84899991797 scopus 로고    scopus 로고
    • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological anti-tumor necrosis factor therapy: 6-month and 1 year results of the phase 3, multicentre, double-blinded, placebo-controlled, randomized PSUMMIT 2 trial
    • 64 Richlin, C., Rahman, P., Kavanaugh, A., et al., on behalf of the PSUMIIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological anti-tumor necrosis factor therapy: 6-month and 1 year results of the phase 3, multicentre, double-blinded, placebo-controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis 73 (2014), 990–999.
    • (2014) Ann Rheum Dis , vol.73 , pp. 990-999
    • Richlin, C.1    Rahman, P.2    Kavanaugh, A.3
  • 65
    • 84973345521 scopus 로고    scopus 로고
    • Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomized phase III trial (FUTURE 1)
    • 65 Strand, V., Mease, P., Gossec, L., Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomized phase III trial (FUTURE 1). Ann Rheum Dis 76:1 (2017), 203–207.
    • (2017) Ann Rheum Dis , vol.76 , Issue.1 , pp. 203-207
    • Strand, V.1    Mease, P.2    Gossec, L.3
  • 66
    • 84942198180 scopus 로고    scopus 로고
    • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial
    • 66 McInnes, I.B., Mease, P.J., Kirkham, B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1137–1146.
    • (2015) Lancet , vol.386 , pp. 1137-1146
    • McInnes, I.B.1    Mease, P.J.2    Kirkham, B.3
  • 67
    • 77954651554 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated vasculitis
    • 67 Stone, J.H., Merkel, P.A., Spiera, R., et al. Rituximab versus cyclophosphamide in ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
    • (2010) N Engl J Med , vol.363 , pp. 221-232
    • Stone, J.H.1    Merkel, P.A.2    Spiera, R.3
  • 68
    • 77954632414 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    • 68 Jones, R.B., Tervaert, J.W., Hauser, T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (2010), 211–220.
    • (2010) N Engl J Med , vol.363 , pp. 211-220
    • Jones, R.B.1    Tervaert, J.W.2    Hauser, T.3
  • 69
    • 84935002700 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of randomized trial
    • 69 Jones, R.B., Furuta, S., Tervaert, J.W., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of randomized trial. Ann Rheum Dis 74 (2015), 1178–1182.
    • (2015) Ann Rheum Dis , vol.74 , pp. 1178-1182
    • Jones, R.B.1    Furuta, S.2    Tervaert, J.W.3
  • 70
    • 84908576790 scopus 로고    scopus 로고
    • Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
    • 70 Guillevin, L., Pagnouz, C., Karra, S., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 (2014), 1771–1780.
    • (2014) N Engl J Med , vol.371 , pp. 1771-1780
    • Guillevin, L.1    Pagnouz, C.2    Karra, S.3
  • 71
    • 84919476951 scopus 로고    scopus 로고
    • The role of biological agents in the management of large vessel vasculitis (LVV): a systemic review and meta-analysis
    • 71 Osman, M., Pagnoux, C., Dryden, D.M., et al. The role of biological agents in the management of large vessel vasculitis (LVV): a systemic review and meta-analysis. PLoS One, 9(12), 2014, e115026.
    • (2014) PLoS One , vol.9 , Issue.12 , pp. e115026
    • Osman, M.1    Pagnoux, C.2    Dryden, D.M.3
  • 72
    • 84982803848 scopus 로고    scopus 로고
    • Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients
    • 72 Regent, A., Redeker, S., Deroux, A., et al. Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol 43:8 (2016), 1547–1552.
    • (2016) J Rheumatol , vol.43 , Issue.8 , pp. 1547-1552
    • Regent, A.1    Redeker, S.2    Deroux, A.3
  • 73
    • 84962235379 scopus 로고    scopus 로고
    • Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis [abstract]
    • Available at: Accessed June 29, 2016.
    • 73 Tuckwell, K., Collinson, N., Klearman, M., et al. Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis [abstract]. Arthritis Rheumatol, 67(Suppl 10), 2015 Available at: http://acrabstracts.org/abstract/baseline-data-on-patients-enrolled-in-a-randomized-double-blind-trial-of-tocilizumab-in-giant-cell-arteritis/. Accessed June 29, 2016.
    • (2015) Arthritis Rheumatol , vol.67
    • Tuckwell, K.1    Collinson, N.2    Klearman, M.3
  • 74
    • 34047174085 scopus 로고    scopus 로고
    • A pilot study of IL-1 inhibition by anakinra in acute gout
    • 74 So, A., Smedt, D.E., Revaz, S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res, 9(2), 2007, R28.
    • (2007) Arthritis Res , vol.9 , Issue.2 , pp. R28
    • So, A.1    Smedt, D.E.2    Revaz, S.3
  • 75
    • 84896700469 scopus 로고    scopus 로고
    • Anti-interleukin-1 therapy in the management of gout
    • 75 Schlesinger, N., Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep, 16, 2014, 398.
    • (2014) Curr Rheumatol Rep , vol.16 , pp. 398
    • Schlesinger, N.1
  • 76
    • 84867405545 scopus 로고    scopus 로고
    • Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
    • 76 Schlesinger, N., De Meulemeester, M., Pikhlak, A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:11 (2012), 1839–1848.
    • (2012) Ann Rheum Dis , vol.71 , Issue.11 , pp. 1839-1848
    • Schlesinger, N.1    De Meulemeester, M.2    Pikhlak, A.3
  • 77
    • 85016516689 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy. In: ClinicalTrials.gov [Internet]
    • National Library of Medicine (US) Bethesda (MD) Available at: Accessed Jun 28, 2016. Identifier: NCT02265705
    • 77 Eli Lily and Company, A randomized, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02265705 Accessed Jun 28, 2016. Identifier: NCT02265705.
    • (2000)
    • Eli Lily and Company1
  • 78
    • 85016460898 scopus 로고    scopus 로고
    • US Food and Drug Administration Web site. Available at: Last updated: daily. Accessed June 15.
    • 78 FDA approved drug products. US Food and Drug Administration Web site. Available at: https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name Last updated: daily. Accessed June 15, 2016.
    • (2016)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.